Become a member

Get the best offers and updates relating to Liberty Case News.

― Advertisement ―

StartBiotechnologieVizgen Expands Single-Cell Spatial Transcriptomics Offering with Introduction of MERSCOPE® Ultra Platform...

Vizgen Expands Single-Cell Spatial Transcriptomics Offering with Introduction of MERSCOPE® Ultra Platform and MERFISH 2.0 Chemistry

MERSCOPE Ultra, with a 3x larger imaging area, double the speed, and improved MERFISH sensitivity, will provide researchers with increased sample flexibility and throughput, accelerating advancements in human and translational research.

Vizgen, Inc. the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, unveils the MERSCOPE® Ultra Platform and MERFISH 2.0 chemistry.

The MERSCOPE Ultra Platform is a powerful new high plex in situ spatial multiomic analysis system. The MERSCOPE Ultra features the optimum combined capabilities of imaging area and throughput in a spatial transcriptomics imaging platform. The platform is capable of processing 3 cm2 of tissue on a single slide and acquires images at more than double the speed of the MERSCOPE Platform. Engineered for high-performance and optimized for throughput, MERSCOPE Ultra provides researchers with an industry-leading combination of imageable area, speed, and data quality to accelerate discovery and maximize the biology measured from every sample. Further, the system is the only spatial platform to offer two different size flow cells enabling users to adjust reagent consumption based on area imaged.

Vizgen’s MERFISH 2.0 chemistry leverages improved RNA anchoring and signal enhancement to increase MERFISH’s sensitivity and reproducibility. The optimized chemistry enables broader sample compatibility, improving MERFISH’s performance in archival Formalin-Fixed Paraffin-Embedded (FFPE) samples, and further improving its sensitivity. The company is presenting a poster at AACR showcasing improved sensitivity, reproducibility, and biological accuracy in degraded RNA cancer samples to demonstrate the power of this enhanced chemistry.

“MERSCOPE Ultra elevates our in situ imaging capabilities to unprecedented heights, delivering enhanced throughput and adaptability that supports a range of research to accelerate discovery and biological insights,” said Terry Lo, President and CEO of Vizgen. “MERFISH 2.0 chemistry further improves on MERFISH technology, particularly in FFPE and archival samples. Along with our recent addition of 1000 plex custom panel design capabilities, these solutions provide researchers with a powerful spatial omics solution.”.

Interested in learning more about Vizgen’s new MERSCOPE Ultra Platform? Contact us, and we will be happy to provide you detailed information!

Picture: Bucher Biotec AG

https://www.bucher.ch